Genetically engineered mouse models of pancreatic adenocarcinoma

Molecular Oncology

Volumn 7, Issue 2, 2013, Pages 232-247

  Guerra, Carmen ^a   Barbacid, Mariano ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

Cancer models; Inflammation; Pancreatic ductal adenocarcinoma; Target validation; Therapeutic strategies; Tumor microenvironment

Indexed keywords

CRE RECOMBINASE; CYCLOOXYGENASE 2; CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GAMMA SECRETASE INHIBITOR; GEMCITABINE; K RAS PROTEIN; MATRILYSIN; MRK 003; MUCIN; PACLITAXEL; PROTEIN KINASE LKB1; PROTEIN P53; SARIDEGIB; SMAD4 PROTEIN; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG;

ACINAR CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MODEL; CANCER SIZE; CYSTIC NEOPLASM; EMBRYO CELL; EMBRYO DEVELOPMENT; HUMAN; INTRACELLULAR SIGNALING; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATIC STELLATE CELL; PANCREATITIS; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; REVIEW; TRANSGENE; TRANSGENIC MOUSE;

ANIMALIA; MUS;

EID: 84875811505     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.02.002     Document Type: Review

References (115)

1. Aguirre A.J., Bardeesy N., Sinha M., Lopez L., Tuveson D.A., Horner J., Redston M.S., DePinho R.A. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003, 17:3112-3126.
2. Apelqvist A., Li H., Sommer L., Beatus P., Anderson D.J., Honjo T., Hrabe de Angelis M., Lendahl U., Edlund H. Notch signalling controls pancreatic cell differentiation. Nature 1999, 400:877-881.
3. Apte M.V., Wilson J.S. Dangerous liaisons: pancreatic stellate cells and pancreatic cancer cells. J. Gastroenterol. Hepatol. 2012, 27:69-74.
4. Ardito C.M., Gruner B.M., Takeuchi K.K., Lubeseder-Martellato C., Teichmann N., Mazur P.K., DelGiorno K.E., Carpenter E.S., Halbrook C.J., Hall J.C., Pal D., Briel T., Herner A., Trajkovic-Arsic M., Sipos B., Liou G.-Y., Storz P., Murray N.R., Threadgill D.W., Sibilia M., Washington M.K., Wilson C.L., Schmid R.M., Raines E.W., Crawford H.C., Siveke J.T. EGF Receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 2012, 22:304-317.
5. Bardeesy N., Cheng K.H., Berger J.H., Chu G.C., Pahler J., Olson P., Hezel A.F., Horner J., Lauwers G.Y., Hanahan D., DePinho R.A. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006, 20:3130-3146.
6. Bayne L.J., Beatty G.L., Jhala N., Clark C.E., Rhim A.D., Stanger B.Z., Vonderheide R.H. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012, 21:822-835.
7. Beatty G.L., Chiorean E.G., Fishman M.P., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., Huhn R.D., Song W., Li D., Sharp L.L., Torigian D.A., O'Dwyer P.J., Vonderheide R.H. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
8. Bonifazi M., Gallus S., Bosetti C., Polesel J., Serraino D., Talamini R., Negri E., La Vecchia C. Aspirin use and pancreatic cancer risk. Eur. J. Cancer Prev. 2010, 19:352-354.
9. Bradley M.C., Hughes C.M., Cantwell M.M., Napolitano G., Murray L.J. Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested casecontrol study. Br. J. Cancer 2010, 102:1415-1421.
10. Brembeck F.H., Schreiber F.S., Deramaudt T.B., Deramaudt T.B., Craig L., Rhoades B., Swain G., Grippo P., Stoffers D.A., Silberg D.G., Rustgi A.K. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice. Cancer Res. 2003, 63:2005-2009.
11. Brune K., Abe T., Canto M., O'Malley L., Klein A.P., Maitra A., Volkan A.N., Fishman E.K., Cameron J.L., Yeo C.J., Kern S.E., Goggins M., Hruban R.H. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am. J. Surg. Pathol. 2006, 30:1067-1076.
12. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
13. Campbell P.J., Yachida S., Mudie L.J., Stephens P.J., Pleasance E.D., Stebbings L.A., Morsberger L.A., Latimer C., McLaren S., Lin M.L., McBride D.J., Varela I., Nik-Zainal S.A., Leroy C., Jia M., Menzies A., Butler A.P., Teague J.W., Griffin C.A., Burton J., Swerdlow H., Quail M.A., Stratton M.R., Iacobuzio-Donahue C., Futreal P.A. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010, 467:1109-1113.
14. Carriere C., Seeley E.S., Goetze T., Longnecker D.S., Korc M. The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:4437-4442.
15. Collins M.A., Bednar F., Zhang Y., Brisset J.C., Galbán S., Galbán C.J., Rakshit S., Flannagan K.S., Adsay N.V., Pasca di Magliano M. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clin. Invest. 2012, 122:639-653.
16. Collisson E.A., Trejo C.L., Silva J.M., Gu S., Korkola J.E., Heiser L.M., Charles R.P., Rabinovich B.A., Hann B., Dankort D., Spellman P.T., Phillips W.A., Gray J.W., McMahon M. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2012, 2:685-693.
17. Cook N., Frese K.K., Bapiro T.E., Jacobetz M.A., Gopinathan A., Miller J.L., Rao S.S., Demuth T., Howat W.J., Jodrell D.I., Tuveson D.A. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J. Exp. Med. 2012, 209:437-444.
18. Corcoran R.B., Contino G., Deshpande V., Tzatsos A., Conrad C., Benes C.H., Levy D.E., Settleman J., Engelman J.A., Bardeesy N. STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res. 2011, 71:5020-5029.
19. De La O L.P., Emerson L.L., Goodman J.L., Froebe S.C., Illum B.E., Curtis A.B., Murtaugh L.C. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:18907-18912.
20. Detlefsen S., Sipos B., Feyerabend B., Klöppel G. Pancreatic fibrosis associated with age and ductal papillary hyperplasia. Virchows Arch. 2005, 447:800-805.
21. Douziech N., Lajas A., Coulombe Z., Calvo E., Lainé J., Morisset J. Growth effects of regulatory peptides and intracellular signaling routes in human pancreatic cancer cell lines. Endocrine 1998, 9:171-183.
22. Feldmann G., Habbe N., Dhara S., Bisht S., Alvarez H., Fendrich V., Beaty R., Mullendore M., Karikari C., Bardeesy N., Ouellette M.M., Yu W., Maitra A. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008, 57:1420-1430.
23. Fendrich V., Esni F., Garay M.V., Feldmann G., Habbe N., Jensen J.N., Dor Y., Stoffers D., Jensen J., Leach S.D., Maitra A. Hedgehog signaling is required for effective regeneration of exocrine pancreas. Gastroenterology 2008, 135:621-631.
24. Frese K.K., Neesse A., Cook N., Bapiro T.E., Lolkema M.P., Jodrell D.I., Tuveson D.A. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012, 2:260-269.
25. Fukuda A., Wang S.C., Morris J.P., Folias A.E., Liou A., Kim G.E., Akira S., Boucher K.M., Firpo M.A., Mulvihill S.J., Hebrok M. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 2011, 19:441-455.
26. Fukuda A., Morris J.P., Hebrok M. Bmi1 is required for regeneration of the exocrine pancreas in mice. Gastroenterology 2012, 143:821-831.
27. Furukawa T., Kuboki Y., Tanji E., Yoshida S., Hatori T., Yamamoto M., Shibata N., Shimizu K., Kamatani N., Shiratori K. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci. Rep. 2011, 1:161.
28. Furuyama K., Kawaguchi Y., Akiyama H., Horiguchi M., Kodama S., Kuhara T., Hosokawa S., Elbahrawy A., Soeda, Koizumi T.M., Masui T., Kawaguchi M., Takaori K., Doi R., Nishi E., Kakinoki R., Deng J.M., Behringer R.R., Nakamura T., Uemoto S. Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nat. Genet. 2011, 43:34-41.
29. Gidekel-Friedlander S.Y., Chu G.C., Snyder E.L., Girnius N., Dibelius G., Crowley D., Vasile E., DePinho R.A., Jacks T. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell 2009, 16:379-389.
30. Goggins M., Shekher M., Turnacioglu K., Yeo C.J., Hruban R.H., Kern S.E. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res. 1998, 58:5329-5332.
31. Gopinathan A., Denicola G.M., Frese K.K., Cook N., Karreth F.A., Mayerle J., Lerch M.M., Reinheckel T., Tuveson D.A. Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice. Gut 2012, 61:877-884.
32. Gradishar W.J. Albumin-bound paclitaxel: a next-generation taxane. Exp. Opin. Pharmacother. 2006, 7:1041-1053.
33. Guerra C., Schuhmacher A.J., Cañamero M., Grippo P.J., Verdaguer L., Pérez-Gallego L., Dubus P., Sandgren E.P., Barbacid M. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-ras oncogenes in adult mice. Cancer Cell 2007, 11:291-302.
34. Guerra C., Collado M., Navas C., Schuhmacher A.J., Hernández-Porras I., Cañamero M., Rodriguez-Justo M., Serrano M., Barbacid M. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene induced senescence. Cancer Cell 2011, 19:728-739.
35. Guz Y., Montminy M.R., Stein R., Leonard J., Gamer L.W., Wright C.V.E., Teitelman G. Expression of murine STF-1, a putative insulin gene transcription factor, in β-cells of pancreas, duodenal epithelium and pancreatic exocrine and endocrine progenitors during ontogeny. Development 1995, 121:11-18.
36. Habbe N., Shi G., Meguid R.A., Fendrich V., Esni F., Chen H., Feldmann G., Stoffers D.A., Konieczny S.F., Leach S.D., Maitra A. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:18913-18918.
37. Hahn S.A., Schutte M., Hoque A.T., Moskaluk C.A., da Costa L.T., Rozenblum E., Weinstein C.L., Fischer A., Yeo C.J., Hruban R.H., Kern S.E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996, 271:350-353.
38. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985, 315:115-122.
39. Hanlon L., Avila J.L., Demarest R.M., Troutman S., Allen M., Ratti F., Rustgi A.K., Stanger B.Z., Radtke F., Adsay V., Long F., Capobianco A.J., Kissil J.L. Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res. 2010, 70:4280-4286.
40. Hidalgo M. Pancreatic cancer. N. Engl. J. Med. 2010, 362:1605-1617.
41. Hingorani S.R., Petricoin E.F., Maitra A., Rajapakse V., King C., Jacobetz M.A., Ross S., Conrads T.P., Veenstra T.D., Hitt B.A., Kawaguchi Y., Johann D., Liotta L.A., Crawford H.C., Putt M.E., Jacks T., Wright Ch.V.E., Hruban R.A., Lowy A.M., Tuveson D.A. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4:437-450.
42. Hingorani S.R., Wang L., Multani A.S., Combs C., Deramaudt T.B., Hruban R.H., Rustgi A.K., Chang S., Tuveson D.A. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7:469-483.
43. Hruban R.H., Wilentz R.E., Kern S.E. Genetic progresión in the pancreatic ducts. Am. J. Pathol. 2000, 156:1821-1825.
44. Hruban R.H., Wilentz R.E., Maitra A. Identification and analysis of precursors to invasive pancreatic cancer. Methods Mol. Med. 2005, 103:1-13.
45. Hruban R.H., Canto M., Goggins M., Schulick R., Klein A.P. Update on familial pancreatic cancer. Adv. Surg. 2010, 44:293-311.
46. Huang C., Huang R., Chang W., Jiang T., Huang K., Cao J., Sun X., Qiu Z. The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma. Neoplasma 2012, 59:52-61.
47. Hwang R.F., Moore T., Arumugam T., Ramachandran V., Amos K.D., Rivera A., Ji B., Evans D.B., Logsdon C.D. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 2008, 68:918-926.
48. Hwang R.F., Moore T.T., Hattersley M., Scarpitti M., Yang B., Devereaux E., Ramachandran V., Arumugam T., Ji B., Logsdon C.D., Brown J.L., Godin R. Inhibition of the Hedgehog pathway targets the tumor-associated stroma in pancreatic cancer. Mol. Cancer Res. 2012, 10:1147-1157.
49. Ijichi H., Chytil A., Gorska A.E., Aakre M.E., Fujitani Y., Fujitani S., Wright C.V., Moses H.L. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev. 2006, 20:3147-3160.
50. Ijichi H., Chytil A., Gorska A.E., Aakre M.E., Bierie B., Tada M., Mohri D., Miyabayashi K., Asaoka Y., Maeda S., Ikenoue T., Tateishi K., Wright C.V., Koike K., Omata M., Moses H.L. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J. Clin. Invest. 2011, 121:4106-4117.
51. Izeradjene K., Combs C., Best M., Gopinathan A., Wagner A., Grady W.M., Deng C.X., Hruban R.H., Adsay N.V., Tuveson D.A., Hingorani S.R. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 2007, 11:229-243.
52. Jacobetz M.A., Chan D.S., Neesse A., Bapiro T.E., Cook N., Frese K.K., Feig C., Nakagawa T., Caldwell M.E., Zecchini H.I., Lolkema M.P., Jiang P., Kultti A., Thompson C.B., Maneval D.C., Jodrell D.I., Frost G.I., Shepard H.M., Skepper J.N., Tuveson D.A. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013, 62:112-120.
53. Jensen J.N., Cameron E., Garay M.V., Starkey T.W., Gianani R., Jensen J. Recapitulation of elements of embryonic development in adult mouse pancreatic regeneration. Gastroenterology 2005, 128:728-741.
54. Jimenez R.E., Warshaw A.L., Z'graggen K., Hartwig W., Taylor D.Z., Compton C.C., Fernández-del Castillo C. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann. Surg. 1999, 230:501-509. discussion 509-511.
55. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
56. Karapetis C.S., Khambata-Ford S., Jonker D.J., O'Callaghan C.J., Tu D., Tebbutt N.C., Simes R.J., Chalchal H., Shapiro J.D., Robitaille S., Price T.J., Shepherd L., Au H.J., Langer C., Moore M.J., Zalcberg J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 2008, 359:1757-1765.
57. Keefe M.D., Wang H., De La O J.P., Khan A., Firpo M.A., Murtaugh L.C. Beta-catenin is selectively required for the expansion and regeneration of mature pancreatic acinar cells in mice. Dis. Model. Mech. 2012, 5:503-514.
58. Kopp J.L., von Figura G., Mayes E., Liu F., Dubois C.L., Morris J.P., Pan F.C., Akiyama H., Wright Ch.V.E., Jensen K., Hebrok M., Sander M. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 22:737-750.
59. Korc M. Role of growth factors in pancreatic cancer. Surg. Oncol. Clin. N. Am. 1998, 7:25-41.
60. Kraman M., Bambrough P.J., Arnold J.N., Roberts E.W., Magiera L., Jones J.O., Gopinathan A., Tuveson D.A., Fearon D.T. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010, 330:827-830.
61. Lesina M., Kurkowski M.U., Ludes K., Rose-John S., Treiber M., Klöppel G., Yoshimura A., Reindl W., Sipos B., Akira S., Schmid R.M., Algül H. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011, 19:456-469.
62. Li D., Xie K., Wolff R., Abbruzzese J.L. Pancreatic cancer. Lancet 2004, 363:1049-1057.
63. Lowenfels A.B., Maisonneuve P., Cavallini G., Ammann R.W., Lankisch P.G., Andersen J.R., Dimagno E.P., Andrén-Sandberg A., Domellof L. Pancreatitis and the risk of pancreatic cancer. N. Engl. J. Med. 1993, 328:1433-1437. International Pancreatitis Study Group.
64. Maitra A., Fukushima N., Takaori K., Hruban R.H. Precursors to invasive pancreatic cancer. Adv. Anat. Pathol. 2005, 12:81-91.
65. Malka D., Hammel P., Maire F., Rufat P., Madeira I., Pessione F., Lévy P., Ruszniewski P. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002, 51:849-852.
66. Mazur P.K., Siveke J.T. Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressin translational oncology. Gut 2012, 61:1488-1500.
67. Mazur P.K., Einwachter H., Lee M., Sipos B., Nakhai H., Rad R., Zimber-Strobl U., Strobl L.J., Radtke F., Klöppel G., Schmid R.M., Siveke J.T. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:13438-13443.
68. Miyamoto Y., Maitra A., Ghosh B., Zechner U., Argani P., Iacobuzio-Donahue C.A., Sriuranpong V., Iso T., Meszoely I.M., Wolfe M.S., Hruban R.H., Ball D.W., Schmid R.M., Leach S.D. Notch mediates TGF alphainduced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003, 3:565-576.
69. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., Au H.J., Murawa P., Walde D., Wolff R.A., Campos D., Lim R., Ding K., Clark G., Voskoglou-Nomikos T., Ptasynski M., Parulekar W., National Cancer Institute of Canada Clinical Trials Group Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25:1960-1966.
70. Morris J.P.I.V., Cano D.A., Sekine S., Wang S.C., Hebrok M. Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J. Clin. Invest. 2010, 120:508-520.
71. Morton J.P., Jamieson N.B., Karim S.A., Athineos D., Ridgway R.A., Nixon C., McKay C.J., Carter R., Brunton V.G., Frame M.C., Ashworth A., Oien K.A., Evans T.R., Sansom O.J. LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology 2010, 39:586-597.
72. Navas C., Hernández-Porras I., Schumacher A.J., Sibilia M., Guerra C., Barbacid M. EGF receptor signaling is essential for K-Ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 2012, 22:318-330.
73. Nolan-Stevaux O., Lau J., Truitt M.L., Chu G.C., Hebrok M., Fernández-Zapico M.E., Hanahan D. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev. 2009, 23:24-36.
74. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., Frese K.K., DeNicola G., Christine Feig C., Combs C., Winter S.P., Heather I., Reichelt S., Howat W.J., Chang A., Dhara M., Lifu Wang L., Ruckert F., Grutzmann R., Pilarsky C., Izeradjene K., Hingorani S.R., Huang P., Davies S.E., Plunkett W., Egorin M., Hruban R.H., Whitebread N., McGovern K., Adams J., Iacobuzio-Donahue C., Griffiths J., Tuveson D.A. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
75. Pasca di Magliano M., Sekine S., Ermilov A., Ferris J., Dlugosz A.A., Hebrok M. Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev. 2006, 20:3161-3173.
76. Perez-Mancera P.A., Rust A.G., van der Weyden L., Kristiansen G., Li A., Sarver A.L., Silverstein K.A.T., Grutzmann R., Aust D., Rummele P., Knosel T., Herd C., Stemple D.L., Kettleborough R., Brosnan J.A., Li A., Morgan R., Knight S., Yu J., Stegeman S., Collier L.S., ten Hoeve J.J., Ridder J., Klein A.P., Goggins M., Hruban R.H., Chang D.K., Biankin A.V., Grimmond S.M., Australian Pancreatic Cancer Genome Initiative, Wessels Lodewyk F.A., Wood S.A., Iacobuzio-Donahue Ch.A., Pilarsky Ch., Largaespada D.A., Adams D.J., Tuveson D.A. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 2012, 486:266-270.
77. Perez-Mancera P.A., Guerra C., Barbacid M., Tuveson D.A. What we have learned about pancreatic cancer from mouse models. Gastroenterology 2012, 142:1079-1092.
78. Plentz R., Park J.S., Rhim A.D., Abravanel D., Hezel A.F., Sharma S.V., Gurumurthy S., Deshpande V., Kenific C., Settleman J., Majumder P.K., Stanger B.Z., Bardeesy N. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2009, 136:1741-1749.e6.
79. Prasad N.B., Biankin A.V., Fukushima N., Maitra A., Dhara S., Elkahloun A.G., Hruban R.H., Goggins M., Leach S.D. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res. 2005, 65:1619-1626.
80. Provenzano P.P., Cuevas C., Chang A.E., Goel V.K., Daniel D., Von Hoff D.D., Hingorani S.R. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:418-429.
81. Pylayeva-Gupta Y., Lee K.E., Hajdu C.H., Miller G., Bar-Sagi D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 2012, 21:836-847.
82. Qiu W., Su G.H. Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis. Cancer Metastasis Rev. 2012, (Epub ahead of print).
83. Raimondi S., Lowenfels A.B., Morselli-Labate A.M., Maisonneuve P., Pezzilli R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract. Res. Clin. Gastroenterol. 2010, 24:349-358.
84. Redston M.S., Caldas C., Seymour A.B., Hruban R.H., da Costa L., Yeo C.J., Kern S.E. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. 1994, 54:3025-3033.
85. Rothwell P.M., Fowkes F.G., Belch J.F., Ogawa H., Warlow C.P., Meade T.W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377:31-41.
86. Rovira M., Scott S.G., Liss A.S., Jensen J., Thayer S.P., Leach S.D. Isolation and characterization of centroacinar/terminal ductal progenitor cells in adult mouse pancreas. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:75-80.
87. Rowley M., Ohashi A., Mondal G., Mills L., Yang L., Zhang L., Sundsbak R., Shapiro V., Muders M.H., Smyrk T., Couch F.J. Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology 2011, 140:1303-1313.e1-3.
88. Sangiorgi E., Capecchi M.R. Bmi1 lineage tracing identifies a selfrenewing pancreatic acinar cell subpopulation capable of maintaining pancreatic organ homeostasis. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:7101-7106.
89. Schwickart M., Huang X., Lill J.R., Liu J., Ferrando R., French D.M., Maecker H., O'Rourke K., Bazan F., Eastham-Anderson J., Yue P., Dornan D., Huang D.C., Dixit V.M. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010, 463:103-107.
90. Sclabas G.M., Fujioka S., Schmidt C., Evans D.B., Chiao P.J. NF-kB in pancreatic cancer. Int. J. Gastrointest. Cancer 2003, 33:15-26.
91. Shi C., Hong S.M., Lim P., Kamiyama H., Khan M., Anders R.A., Goggins M., Hruban R.H., Eshleman J.R. KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin. Mol. Cancer Res. 2009, 7:230-236.
92. Shields D.J., Murphy E.A., Desgrosellier J.S., Mielgo A., Lau S.K.M., Barnes L.A., Lesperance J., Huang M., Schmedt C., Tarin D., Lowy A.M., Cheresh D.A. Oncogenic Ras/Src cooperativity in pancreatic neoplasia. Oncogene 2011, 30:2123-2134.
93. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., Fong K.M., Lee H., Toyooka S., Shimizu N., Fujisawa T., Feng Z., Roth J.A., Herz J., Minna J.D., Gazdar A.F. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 2005, 97:339-346.
94. Siveke J.T., Einwächter H., Sipos B., Lubeseder-Martellato C., Klöppel G., Schmid R.M. Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell 2007, 12:266-279.
95. Siveke J.T., Lubeseder-Martellato C., Lee M., Mazur P.K., Nakhai H., Radtke F., Schmid R.M. Notch signaling is required for exocrine regeneration after acute pancreatitis. Gastroenterology 2008, 134:544-555.
96. Skoulidis F., Cassidy L.D., Pisupati V., Jonasson J.G., Bjarnason H., Eyfjord J.E., Karreth F.A., Lim M., Barber L.M., Clatworthy S.A., Davies S.E., Olive K.P., Tuveson D.A., Venkitaraman A.R. Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell 2010, 18:499-509.
97. Stanger B.Z., Stiles B., Lauwers G.Y., Bardeesy N., Mendoza M., Wang Y., Greenwood A., Cheng K.-h., McLaughlin M., Brown D., DePinho R.A., Wu H., Melton D.A., Dor Y. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 2005, 8:185-195.
98. Tan X.L., Reid Lombardo K.M., Bamlet W.R., Oberg A.L., Robinson D.P., Anderson K.E., Petersen G.M. Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study. Cancer Prev. Res. (Phila) 2011, 4:1835-1841.
99. Thayer S.P., di Magliano M.P., Heiser P.W., Nielsen C.M., Roberts D.J., Lauwers G.Y., Qi Y.P., Gysin S., Fernández-del Castillo C., Yajnik V., Antoniu B., McMahon M., Warshaw A.L., Hebrok M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425:851-856.
100. Ueda J., Tanaka M., Ohtsuka T., Tokunaga S., Shimosegawa T. Research Committee of Intractable Diseases of the Pancreas. Surgery for chronic pancreatitis decreases the risk for pancreatic cancer: a multicenter retrospective analysis. Surgery 2012, 139:3806-3816.
101. van Heek N.T., Meeker A.K., Kern S.E., Yeo C.J., Lillemoe K.D., Cameron J.L., Offerhaus G.J., Hicks J.L., Wilentz R.E., Goggins M.G., De Marzo A.M., Hruban R.H., Maitra A. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am. J. Pathol. 2002, 161:1541-1547.
102. Vincent D.F., Yan K.P., Treilleux I., Gay F., Arfi V., Kaniewski B., Marie J.C., Lepinasse F., Martel S., Goddard-Leon S., Iovanna J.L., Dubus P., Garcia S., Puisieux A., Rimokh R., Bardeesy N., Scoazec J.Y., Losson R., Bartholin L. Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet. 2009, 5:e1000575.
103. Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet 2011, 378:607-620.
104. Von Hoff D.D., Ramanathan R.K., Borad M.J., Laheru D.A., Smith L.S., Wood T.E., Korn R.L., Desai N., Trieu V., Iglesias J.L., Zhang H., Soon-Shiong P., Shi T., Rajeshkumar N.V., Maitra A., Hidalgo M. Gemcitabine plus nabpaclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol. 2011, 29:4548-4554.
105. Wagner M., Greten F.R., Weber C.K., Koschnick S., Mattfeldt T., Deppert W., Kern H., Adler G., Schmid R.M. A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Genes Dev. 2001, 15:286-293.
106. Westphalen C.B., Olive K.P. Genetically engineered mouse models of pancreatic cancer. Cancer J. 2012, 18:502-510.
107. Wilentz R.E., Geradts J., Maynard R., Offerhaus G.J., Kang M., Goggins M., Yeo C.J., Kern S.E., Hruban R.H. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res. 1998, 58:4740-4744.
108. Wilentz R.E., Albores-Saavedra J., Hruban R.H. Mucinous cystic neoplasms of the pancreas. Semin. Diagn. Pathol. 2000, 17:31-42.
109. Wu K.L., Gannon M., Peshavaria M., Offield M.F., Henderson E., Ray M., Marks A., Gamer L.W., Wright C.V.E., Stein R. Hepatocyte nuclear factor 3β is involved in pancreatic β-cell-specific transcription of the pdx-1 gene. Mol. Cell. Biol. 1997, 17:6002-6013.
110. Wu J., Jiao Y., Dal Molin M., Maitra A., de Wilde R.F., Wood L.D., Eshleman J.R., Goggins M.G., Wolfgang C.L., Canto M.I., Schulick R.D., Edil B.H., Choti M.A., Adsay V., Klimstra D.S., Offerhaus G.J., Klein A.P., Kopelovich L., Carter H., Karchin R., Allen P.J., Schmidt C.M., Naito Y., Diaz L.A., Kinzler K.W., Papadopoulos N., Hruban R.H., Vogelstein B. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:21188-21193.
111. Wu J., Matthaei H., Maitra A., Dal Molin M., Wood L.D., Eshleman J.R., Goggins M., Canto M.I., Schulick R.D., Edil B.H., Wolfgang C.L., Klein A.P., Diaz L.A., Allen P.J., Schmidt C.M., Kinzler K.W., Papadopoulos N., Hruban R.H., Vogelstein B. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci. Transl. Med. 2011, 3:92ra66.
112. Yauch R.L., Gould S.E., Scales S.J., Tang T., Tian H., Ahn C.P., Marshall D., Fu L., Januario T., Kallop D., Nannini-Pepe M., Kotkow K., Marsters J.C., Rubin L.L., de Sauvage F.J. A paracrine requirement for hedgehog signalling in cancer. Nature 2008, 455:406-410.
113. Ying H., Elpek K.G., Vinjamoori A., Zimmerman S.M., Chu G.C., Yan H., Fletcher-Sananikone E., Zhang H., Liu Y., Wang W., Ren X., Zheng H., Kimmelman A.C., Paik J.H., Lim C., Perry S.R., Jiang S., Malinn B., Protopopov A., Colla S., Xiao Y., Hezel A.F., Bardeesy N., Turley S.J., Wang Y.A., Chin L., Thayer S.P., DePinho R.A. Pten is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kappaB-cytokine network. Cancer Discov. 2011, 1:158-169.
114. Yoshida T., Shiraki N., Baba H., Goto M., Fujiwara S., Kume K., Kume S. Expression patterns of epiplakin in pancreas, pancreatic cancer and regenerating pancreas. Genes Cells 2008, 13:667-678.
115. Zhu L., Shi G., Schmidt C.M., Hruban R.H., Konieczny S.F. Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. Am. J. Pathol. 2007, 171:263-273.